{ "meta": { "data_length": 1, "message": "Statement id stmt:ema:tibsovo:0:2 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Atibsovo%3A0%3A2", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002081, "timestamp_received": "2026-10-16T22:55:54.016534+00:00Z", "timestamp_returned": "2026-10-16T22:55:54.018615+00:00Z", "trace_id": "61cebf6b-55d0-4042-9fdf-29e9979db4de" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:ema:tibsovo:0:2", "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2023-05-04:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2023-05-04", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:tibsovo", "type": "Document", "documentType": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "title": null, "aliases": [], "description": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Les Laboratoires Servier.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tibsovo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ivosidenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2023-05-12", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-01-15", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:182", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C3171", "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Acute+Myeloid+Leukemia+%28AML%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C3171", "code": "C3171", "name": "Acute Myeloid Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3171" ] } }, "objectTherapeutic": { "id": "txgrp:33", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C288", "conceptType": "Therapy", "name": "Azacitidine", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1251", "code": "1251", "name": "azacitidine", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1251" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1314865", "code": "1314865", "name": "azacitidine", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1314865" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Hypomethylating agent chemotherapy" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C288", "code": "C288", "name": "Azacitidine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288" ] } }, { "id": "tx:ncit:C114383", "conceptType": "Therapy", "name": "Ivosidenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2049873", "code": "2049873", "name": "ivosidenib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2049873" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1560123", "code": "1560123", "name": "ivosidenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1560123" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "IDH1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:76", "present": true, "subject": { "id": "bmkr:76", "type": "CategoricalVariant", "name": "IDH1 p.R132H", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "type": "Allele", "name": "NP_005887.2:p.Arg132His", "aliases": [ "NP_005887.2:p.R132H", "IDH1 p.R132H" ], "description": "VRS variation of NP_005887.2:p.Arg132His", "digest": "2VAvTmPON2L7JffxjE68jAmmmwxyzDpB", "expressions": [ { "syntax": "hgvs.p", "value": "NP_005887.2:p.Arg132His", "extensions": [ { "name": "hgvs.p_short", "value": "p.R132H" } ] } ], "location": { "id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 132 of the Refseq protein NP_005887.2, which is the protein product of the MANE Select coding transcript for IDH1 (refseq:NM_005896.4).", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": { "id": "ga4gh:SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ", "type": "SequenceReference", "name": "NP_005887.2", "aliases": [ "ensembl:ENSP00000260985.2", "ga4gh:SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ", "refseq:NP_005887.2" ], "description": "The protein product of the MANE Select coding transcript for IDH1 (refseq:NM_005896.4), corresponding to the Refseq protein accession NP_005887.2.", "moleculeType": "protein", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ", "residueAlphabet": "aa" }, "start": 131, "end": 132, "sequence": "R" }, "state": { "type": "LiteralSequenceExpression", "sequence": "H" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:5382", "conceptType": "Gene", "name": "IDH1", "primaryCoding": { "id": "coding:hgnc:5382", "code": "HGNC:5382", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000138413", "code": "ENSG00000138413", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000138413" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:3417", "code": "3417", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/3417" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005896.4", "code": "NM_005896.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "2" }, { "name": "start_position", "value": 209113112 }, { "name": "end_position", "value": 209113112 }, { "name": "reference_allele", "value": "C" }, { "name": "alternate_allele", "value": "T" }, { "name": "cdna_change", "value": "c.395G>A" }, { "name": "protein_change", "value": "p.R132H" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 4 }, { "name": "rsid", "value": "rs121913500" }, { "name": "hgvsg", "value": "2:g.209113112C>T" }, { "name": "hgvsc", "value": "ENST00000345146.2:c.395G>A" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:ema:tibsovo:0", "type": "Indication", "description": "Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2023-05-04:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2023-05-04", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:tibsovo", "type": "Document", "documentType": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "title": null, "aliases": [], "description": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Les Laboratoires Servier.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tibsovo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ivosidenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2023-05-12", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-01-15", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }